Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients.

Autor:	Lee, R.H., Curtis, J., Drake, M.T., Bobo Tanner IV, S., Lenert, L., Schmader, K., Pieper, C., North, R., Lyles, K.W.
Předmět:	INTENSIVE care units RESEARCH COVID-19 DIPHOSPHONATES INTRAVENOUS therapy ACADEMIC medical centers CONFIDENCE intervals ORAL drug administration MECHANICAL ventilators CRITICALLY ill PATIENTS RETROSPECTIVE studies ACQUISITION of data OSTEOPOROSIS ZOLEDRONIC acid HOSPITAL admission & discharge COMPARATIVE studies RESEARCH funding MEDICAL records DESCRIPTIVE statistics LONGITUDINAL method OLD age
Zdroj:	Osteoporosis International; Jan2024, Vol. 35 Issue 1, p181-187, 7p
Abstrakt:	Summary: COVID-19 infection has resulted in significant morbidity and mortality globally, especially among older adults. Repurposed drugs have demonstrated activity in respiratory illnesses, including nitrogen-containing bisphosphonates. In this retrospective longitudinal study at 4 academic medical centers, we show no benefit of nitrogen-containing bisphosphonates regarding ICU admission, ventilator use, and mortality among older adults with COVID-19 infection. We specifically evaluated the intravenous bisphosphonate zoledronic acid and found no difference compared to oral bisphosphonates. Background: Widely used in osteoporosis treatment, nitrogen-containing bisphosphonates (N-BP) have been associated with reduced mortality and morbidity among older adults. Based on prior studies, we hypothesized that prior treatment with N-BP might reduce intensive care unit (ICU) admission, ventilator use, and death among older adults diagnosed with COVID-19. Methods: This retrospective analysis of the PCORnet Common Data Model across 4 academic medical centers through 1 September 2021 identified individuals age >50 years with a diagnosis of COVID-19. The composite outcome included ICU admission, ventilator use, or death within 15, 30, and 180 days of COVID-19 diagnosis. Use of N-BP was defined as a prescription within 3 years prior. ICU admission and ventilator use were determined using administrative codes. Death included both in-hospital and out-of-hospital events. Patients treated with N-BP were matched 1:1 by propensity score to patients without prior N-BP use. Secondary analysis compared outcomes among those prescribed zoledronic acid (ZOL) to those prescribed oral N-BPs. Results: Of 76,223 COVID-19 patients identified, 1,853 were previously prescribed N-BP, among whom 559 were prescribed ZOL. After propensity score matching, there were no significant differences in the composite outcome at 15 days (HR 1.22, 95% CI: 0.89–1.67), 30 days (HR 1.24, 95% CI: 0.93–1.66), or 180 days (HR 1.17, 95% CI: 0.93–1.48), comparing those prescribed and not prescribed N-BP. Compared to those prescribed oral N-BP, there were no significant differences in outcomes among those prescribed ZOL. Conclusion: Among older COVID-19 patients, prior exposure to N-BP including ZOL was not associated with a reduction in ICU admission, ventilator use, or death. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink